This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.
Dr. Kaplan’s research focuses on identifying the molecular mechanisms that promote the initiation and perpetuation of perturbed immune responses and the development of organ damage and premature vascular disease in systemic autoimmunity.
Researchers have identified a potential treatment to reduce the risk of cardiovascular disease in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease.
Dr. Lewandowski leads a team of scientists studying the genetics of early-onset systemic lupus erythematosus patients in populations around the globe. Her research focuses on genetic drivers of severe disease and inflammation in diverse cohorts worldwide.
Dr. Carmelo Carmona-Rivera studies the role of post-translational modifications such as citrullination, carbamylation, and others in the pathogenesis of rheumatoid arthritis, hidradenitis suppurativa, and other autoinflammatory/autoimmune conditions.
What are autoimmune diseases? Autoimmune diseases refer to problems with the immune system, which usually fights off viruses, bacteria, and infection. The problem causes your immune cells to attack your body by mistake. These diseases can affect almost any part of the body.
Scientists can distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.
NIH scientists developed and recently released a free, online data query tool called NeutGX. Researchers around the world can use NeutGX to explore the genetic basis of neutrophil-mediated inflammation in autoimmune diseases, cancer, infectious diseases and other conditions.
Known as the “disease with a thousand faces,” systemic lupus erythematosus is a lifelong autoimmune disease with a wide range of symptoms and signs—fatigue, fever, joint pain, facial rash and skin lesions, shortness of breath, and more. It may develop suddenly or slowly and be mild or severe, with people affected going through periods of flare up and remission of their symptoms.
Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. Findings include the identification of novel molecular signatures related to immune system signaling in kidney cells that may reflect their active role in disease process; molecular targets, including specific white blood cells, for potential treatment in lupus nephritis; and specific types of fibroblasts and white blood cells that are involved in rheumatoid arthritis.
Adeline Chin, a postbaccalaureate research fellow, is searching for proteins present at abnormally high or low levels in the blood of kids with a rare autoimmune illness.
Led by Dr. Mariana Kaplan, the branch studies autoimmune diseases, like lupus and rheumatoid arthritis, seeking treatments and improved outcomes.
Sarthak Gupta, M.D., conducts research to better understand sex differences in neutrophil biology. He is also an investigator on several ongoing clinical trials in systemic lupus erythematosus at the NIH.
What is systemic lupus erythematosus (lupus)? Systemic lupus erythematosus (lupus) is a chronic (long-lasting) autoimmune disease that can affect many parts of the body, including the: Skin. Joints. Heart. Lungs. Kidneys. Brain. Lupus happens when the immune system, which normally helps protect the body from infection and disease, attacks its own tissues. This attack causes inflammation and, in some cases, permanent tissue damage. If you have lupus, you may have times of illness (flares) and times of wellness (remission). Lupus flares can be mild to serious, and they do not follow a pattern. However, with treatment, many people with lupus